First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland

Belzutifan is a new HIF-α inhibitor mainly used in two different indications: von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and pancreatic neuroendocrine tumours, as well as sporadic advanced pre-treated renal cell carcinoma. Although efficacy has been demonstrated i...

Full description

Saved in:

Bibliographic Details
Published in:	Current oncology (Toronto) Vol. 32; no. 2; p. 64
Main Authors:	Peres, Tobias, Aeppli, Stefanie, Fischer, Stefanie, Hundsberger, Thomas, Rothermundt, Christian
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI 26.01.2025 MDPI AG
Subjects:	Adult Aged belzutifan Carcinoma, Renal Cell - drug therapy Case Report case series Female haemangioblastomas HIF-α inhibitor Humans Hypoxia-Inducible Factor 1, alpha Subunit - antagonists & inhibitors Indenes Kidney Neoplasms - drug therapy Male Middle Aged renal cell carcinoma Retrospective Studies Switzerland von Hippel-Lindau Disease - complications von Hippel-Lindau Disease - drug therapy von Hippel–Lindau syndrome Switzerland real-world renal cell carcinoma HIF-α inhibitor belzutifan case series von Hippel–Lindau syndrome haemangioblastomas
ISSN:	1718-7729, 1198-0052, 1718-7729
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!